Author

M. S. Suthar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 19 Microbiology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 23 Research Focus:host-pathogen & immune response· 22 Organism:human· 15 Assay:proteomics· 11 Organism:mouse· 9 Research Focus:cell type annotation· 6 Research Focus:differential expression· 4 Organism:non-human primate· 4

Frequent Co-Authors

M. E. Davis-Gardner· 9 shared L. Lai· 8 shared A. Grakoui· 5 shared B. Pulendran· 5 shared K. Floyd· 5 shared S. Godbole· 5 shared A. Moreno· 4 shared A. Vanderheiden· 4 shared

Activity by Year

2018-2024 · peak 9/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

M. E. Davis-Gardner

Mutual co-authors in cluster

Author profile →

26 papers

Recent·Most cited

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

S. Jain, S. Kumar, L. Lai, S. Linderman, A. A. Malik, M. L. Ellis, S. Godbole, D. Solis, M. K. Sahoo, K. Bechnak, I. Paredes, R. Tanios, B. Kazzi, S. M. Dib, M. B. Litvack, , M. S. Suthar

The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.

bioRxiv · Feb 3, 2024 · PreprintImmunology

CD4+ and CD8+ T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment

M. Kar, K. E. E. Johnson, A. Vanderheiden, E. J. Elrod, K. Floyd, E. Geerling, E. T. Stone, E. Salinas, S. Banakis, W. Wang, S. Sathish, S. Shrihari, M. E. Davis-Gardner, J. Kohlmeier, A. Pinto, , M. S. Suthar

This study shows that CD4+ and CD8+ T cells are necessary to prevent SARS-CoV-2 persistence in the nasal compartment but not in the lungs.

bioRxiv · Jan 23, 2024Immunology

Single cell analysis reveals an antiviral network that controls Zika virus infection in human dendritic cells

K. M. Moore, A.-N. Pelletier, S. Lapp, A. Metz, G. K. Tharp, M. Lee, S. S. Bhasin, M. Bhasin, R.-P. Sekaly, S. E. Bosinger, M. S. Suthar

The paper uses scRNA-seq to analyze the antiviral response in human dendritic cells infected with ZIKV, identifying a network of host genes and proteins involved in antiviral defense.

bioRxiv · Jan 19, 2024Microbiology

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

A. Moreno, K. Manning, M. I. Azeem, A. K. Nooka, M. Ellis, R. J. Manalo, J. M. Switchenko, B. Wali, J. L. Kaufman, C. C. Hofmeister, N. S. Joseph, S. Lonial, K. M. Dhodapkar, M. V. Dhodapkar, M. S. Suthar

This study examines how SARS-CoV-2 booster vaccines affect antibody profiles in myeloma patients, finding improved binding but not neutralization against variants.

bioRxiv · Aug 17, 2023 · PreprintImmunology

Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

Y. Feng, M. Yuan, J. M. Powers, M. Hu, J. E. Munt, P. S. Arunachalam, S. R. Leist, L. Bellusci, L. E. Adams, S. Sundaramurthy, L. M. Shirreff, M. L. Mallory, T. D. Scooby, A. Moreno, D. T. OHagan, , B. Pulendran

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

bioRxiv · Jan 19, 2023 · PreprintImmunology

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

M. E. Davis-Gardner, L. Lai, B. Wali, H. Samaha, D. Solis, M. Lee, A. Porter-Morrison, I. T. Hentenaar, F. Yamamoto, S. Godbole, D. C. Douek, F. E.-H. Lee, N. Rouphael, A. Moreno, B. A. Pinsky, M. S. Suthar

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

bioRxiv · Oct 31, 2022 · PreprintImmunology

Inhibition of CHK2 dependent DNA damage response suppresses Zika virus infection through a STING dependent mechanism

H. Ma, C. Li, Y. Wang, E. V. Valore, M. Trisal, H. Sai-yin Hui, P. Hakimpour, J. R. Bowen, T. W. Mak, M. S. Suthar, B. Pulendran

This study shows that inhibiting CHK2 reduces ZIKV production and rescues developmental defects by enhancing STING-dependent antiviral responses.

bioRxiv · Oct 3, 2022 · PreprintImmunology

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

bioRxiv · Jul 29, 2022 · PreprintImmunology

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody

S. Kumar, A. Patel, L. Lai, C. Chakravarthy, R. Valanparambil, M. E. Davis-Gardner, V. V. Edara, S. Linderman, E. S. Reddy, K. Gottimukkala, K. Nayak, P. Bajpai, V. Singh, F. Frank, N. Cheedarla, , A. Chandele

This paper identifies and structurally analyzes an antibody that neutralizes SARS-CoV-2 BA.1 and BA.2 variants, revealing its unique epitope and mechanism of action.

bioRxiv · May 13, 2022Immunology

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

bioRxiv · Mar 18, 2022 · PreprintImmunology

Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

R. Bommireddy, S. Stone, N. Bhatnagar, P. Kumari, L. E. Munoz, J. Oh, K.-H. Kim, J. T. Berry, K. Jacobsen, J. Lahcen, S.-H. Naing, A. N. Blackerby, T. V. d. Gaag, C. N. Wright, L. Lai, , P. Selvaraj

This study develops a hybrid vaccine combining influenza VLPs with SARS-CoV-2 RBD and GM-CSF, showing protection against both viruses in mice.

bioRxiv · Feb 1, 2022Immunology

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

V.-V. Edara, K. E. Manning, M. Ellis, L. Lai, K. M. Moore, S. L. Foster, K. Floyd, M. E. Davis-Gardner, G. Mantus, L. E. Nyhoff, S. Bechnack, G. Alaaeddine, A. Naji, H. Samaha, M. Lee, , M. S. Suthar

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

bioRxiv · Dec 20, 2021Immunology

Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission

K. Ganti, A. C. Lowen, L. M. Ferreri, C.-Y. Lee, C. R. Bair, G. K. Delima, K. E. Holmes, M. S. Suthar

This study shows that the timing of SARS-CoV-2 exposure, particularly during peak viral load, is the strongest determinant of transmission success in golden Syrian hamsters.

bioRxiv · Dec 8, 2021Microbiology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence

A. Talla, S. V. Vasaikar, M. P. Lemos, Z. Moodie, M.-P. L. Pebworth, K. E. Henderson, K. W. Cohen, J. L. Czartoski, L. Lai, M. S. Suthar, A. T. Heubeck, P. C. Genge, C. R. Roll, M. Weiss, J. Reading, , T. F. Bumol

The paper profiles longitudinal immune responses in mild COVID-19 patients to identify recovery and persistence signatures.

bioRxiv · May 26, 2021 · PreprintImmunology

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

A. Pegu, S. E. O'Connell, S. D. Schmidt, S. O'Dell, C. A. Talana, L. Lai, J. Albert, E. Anderson, H. Bennett, K. Corbett, B. Flach, L. Jackson, B. Leav, J. E. Ledgerwood, C. J. Luke, , N. A. Doria-Rose

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

bioRxiv · May 13, 2021 · PreprintImmunology

Plasmacytoid dendritic cells produce type I interferon and reduce viral replication in airway epithelial cells after SARS-CoV-2 infection

L. Cervantes-Barragan, A. Vanderheiden, C. J. Royer, M. E. Davis-Gardner, P. Ralfs, T. Chirkova, L. J. Anderson, A. Grakoui, M. S. Suthar

This study shows that plasmacytoid dendritic cells recognize SARS-CoV-2, produce type I and III interferons, and reduce viral replication in infected airway epithelial cells.

bioRxiv · May 12, 2021 · PreprintImmunology

Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

A. Muruato, M. Vu, B. A. Johnson, M. Davis-Gardner, A. R. Vanderheiden, K. Lokugamage, C. Schindewolf, P. A. Crocquet-Valdes, R. M. Langsjoen, J. A. Plante, K. S. Plante, S. C. Weaver, K. Debbink, A. L. Routh, D. H. Walker, , V. D. Menachery

This study creates a mouse-adapted SARS-CoV-2 strain that protects mice from lethal SARS-CoV challenge, demonstrating cross-strain immunity.

bioRxiv · May 3, 2021Microbiology

CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infection

A. Vanderheiden, J. Thomas, A. L. Soung, M. E. Davis-Gardner, K. Floyd, F. Jin, D. A. Cowan, K. Pellegrini, A. Creanga, A. Pegu, A. Derrien-Colemyn, P.-Y. Shi, A. Grakoui, R. S. Klein, S. E. Bosinger, , M. S. Suthar

This study identifies a CCR2-dependent monocyte-derived cell mechanism that restricts SARS-CoV-2 infection and inflammation in the lungs of mice.

bioRxiv · May 3, 2021 · PreprintImmunology

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

V. V. Edara, C. Norwood, K. Floyd, L. Lai, M. E. Davis-Gardner, W. H. Hudson, G. Mantus, L. E. Nyhoff, M. W. Adelman, R. Fineman, S. Patel, R. Byram, D. N. Gomes, G. Michael, H. Abdullahi, , M. S. Suthar

The paper compares antibody binding and neutralization against SARS-CoV-2 B.1 and B.1.351 variants in infected and vaccinated individuals, finding reduced titers but retained neutralization.

bioRxiv · Feb 20, 2021 · PreprintImmunology

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

N. K. Routhu, S. Gangadhara, N. Cheedarla, A. Shiferaw, S. A. Rahman, A. Sahoo, P.-Y. Shi, V. D. Menachery, K. Floyd, S. Fischinger, C. Atyeo, G. Alter, M. S. Suthar, R. R. Amara

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

bioRxiv · Jun 27, 2020 · PreprintImmunology

Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

A. Vanderheiden, P. Ralfs, T. Chirkova, A. A. Upadhyay, M. G. Zimmerman, S. Bedoya, H. Aoued, G. K. Tharp, K. Pellegrini, A. C. Lowen, V. D. Menachery, L. J. Anderson, A. Grakoui, S. E. Bosinger, M. S. Suthar

This study shows SARS-CoV-2 infects human airway epithelial cultures, induces pro-inflammatory cytokines, and is inhibited by type I and III IFNs.

bioRxiv · May 19, 2020Microbiology

STAT5: A Target of Antagonism by Neurotropic Flaviviruses

M. G. Zimmerman, J. R. Bowen, C. E. McDonald, E. Young, R. S. Baric, B. Pulendran, M. S. Suthar

The paper identifies STAT5 as a target of antagonism by WNV and ZIKV in human DCs, showing differential inhibition of Jak kinases compared to other flaviviruses.

bioRxiv · Apr 12, 2019Microbiology

West Nile Virus Subverts T Cell Stimulatory Capacity of Human Dendritic Cells

M. G. Zimmerman, J. R. Bowen, C. E. McDonald, B. Pulendran, M. S. Suthar

This study shows West Nile virus infects human dendritic cells, activates antiviral responses, but suppresses T cell activation and cytokine production, impairing T cell immunity.

bioRxiv · Apr 9, 2019 · PreprintMicrobiology

West Nile virus-inclusive single-cell RNA sequencing reveals heterogeneity in the type I interferon response within single cells

J. T. O'Neal, A. A. Upadhyay, A. Wolabaugh, N. B. Patel, S. E. Bosinger, M. S. Suthar

The paper uses WNV-inclusive scRNA-seq to show single-cell heterogeneity in IFN-I response and viral RNA abundance during WNV infection.

bioRxiv · Oct 4, 2018Microbiology